PT 141 10mg
Also known as PT141, PT-141, Bremelanotide, PT 141 Peptide
PT-141, or Bremelanotide, is a research peptide that’s currently being tested for its effects on sexual dysfunction. PT 141 is a metabolite of Melanotan 2, or MT-2 (the tanning peptide), that’s missing the C Terminal amide group. PT 141 is a peptide which is a chain of 2 or more amino acids linked by amide bonds. Amide bonds are also called peptide bonds. The Bremelanotide peptide is a chain of amino acids in the following sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.
Molecular Formula: C50H68N14O10
PT-141 Structural Names: cyclo-[Nle4, Asp5, D-Phe7, Lys10]alpha-MSH-(4-10)
CAS number: 189691-06-3
Molar Mass: 1025.2 g/mol
PubChem: CID 9941379
The development of Bremelanotide started with scientific experiments using a-MSH, α-Melanocyte-stimulating hormone, on rats in the 1960’s. The most notable Melanocyte-stimulating hormones are melanotropins. Melanotropins stimulate melanogenesis which is a process in mammals that controls the hair and skin’s pigmentation. It also has properties that contribute to energy homeostasis, feeding behavior and sexual function.
In the 1980’s University of Arizona, scientists started to research and development of a-MSHs and some other analogs as skin tanning agents. Two of the analogs they tested were Melanotan 1 and Melanotan 2 (Melanotan II).
A scientist name Mac Hadley conducted Melanotan 2 experiments on himself. He doubled the dose and experienced an erection lasting 8 hours along with vomiting and nausea.
Difference between PT-141 and Melanotan 2
Melanotan 1 went on to be licensed as a tanning agent by an Australian pharmaceutical company. Melanotan 2 was licensed by another company to pursue the erectile dysfunction application. MT-2 proved to have more pigmentation qualities than it did for ED, however it led to the development of a derivative PT 141, also known as Bremelanotide.
PT-141 is slightly chemically different than MT-2. PT 141 has a hydroxyl group whereas Melanotan II has an amide group. Compared to other erectile dysfunction medications, Bremelanotide is unique in that it doesn’t work on the vascular system. This means its potential application may apply to both males and females.
In 2004, the development of an intranasal bremelanotide started in full force in the US and several other countries. Clinical trials began to test the results on male erectile dysfunction ED as well as female sexual dysfunction FSD. Unfortunately, in 2007 the FDA stopped the trials because subjects showed an increase in blood pressure.
As a solution, they reformulated Bremelanotide and trials began again. This time the delivery method changed injection, which showed a decrease in the level of blood pressure rise. The trials continued successfully.
Buy PT 141 or Buy Bremelanotide today.